<DOC>
	<DOCNO>NCT02563548</DOCNO>
	<brief_summary>This phase 1b study evaluate combination PEGPH20 pembrolizumab subject relapsed/refractory advanced metastatic Non Small Cell Lung Cancer ( NSCLC ) fail least 1 platinum-based chemotherapy regimen subject relapsed/refractory locally advanced metastatic gastric adenocarcinoma fail least 1 chemotherapy regimen .</brief_summary>
	<brief_title>Phase 1b Open-Label Study PEGPH20 With Pembrolizumab</brief_title>
	<detailed_description>This phase 1b study subject relapsed/refractory advanced metastatic NSCLC fail least 1 platinum-based chemotherapy regimen subject relapsed/refractory locally advanced metastatic gastric adenocarcinoma fail least 1 chemotherapy regimen . This study consist Phase 1b dose escalation portion determine maximum tolerate dose ( MTD ) either 1.6 , 2.2 , 2.6 , 3.0 , 4.0 ug/kg ( high dos necessary ) PEGPH20 combination Pembrolizumab . Once recommended phase 2 dose identify escalation portion , additional patient select high-HA tumor enrol dose expansion portion</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically confirm document , previously treat stage IIIB IV Non Small Cell Lung Cancer ( NSCLC ) fail least 1 previous platinum contain chemotherapy regimen locally advance metastatic disease relapsed/refractory locally advance metastatic gastric adenocarcinoma fail least 1 previous chemotherapy regimen locally advance metastatic disease . Subjects NSCLC know epidermal growth factor receptor ( EGFR ) mutation positive must receive EGFR inhibitor subject know anaplastic lymphoma kinase ( ALK ) mutation positive must receive ALK inhibitor . Prior enrollment , confirmation follow must obtain : Dose escalation For subject dose escalation portion study , prefer available archived tumor tissue formalinfixed paraffinembedded ( FFPE ) block 510 unstained core biopsy slide meet specific tissue sample requirement , however mandatory enrollment portion study . Dose expansion For subject dose expansion portion study , mandatory available archive tumor tissue FFPE block minimum 10 unstained consecutive core biopsy slide 1 archival block meet specific tissue requirement available . One tumor measurable CT scan/MRI scan per RECIST v 1.1 . Previously irradiate tumor may eligible clearly progressed size . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Life expectancy â‰¥3 month . Previous treatment pembrolizumab , nivolumab , program cell death1 antibody ( anti PD1 ) PD1 ligandantibody ( antiPDL1 ) agent . New York Heart Association Class III IV ( Appendix D ) cardiac disease myocardial infarction within past 12 month screen , preexist atrial fibrillation . Prior history cerebrovascular accident transient ischemic attack . NSCLC subject know brain metastasis ( certain exception allow ) Gastric adenocarcinoma subject brain metastasis History active bleeding within last 3 month require transfusion AntiVEGF therapy within last month Patients know interstitial fibrosis interstitial lung disease . Previous history pulmonary embolism pulmonary embolism find screen exam . Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . History another primary cancer within last 3 year require treatment , exception nonmelanoma skin cancer , earlystage prostate cancer , curatively treated cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>